A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa.

Wednesday, September 20, 2023 Clinical Trial of HIV Vaccine Begins in United States and South Africa A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa. The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific immune response in people. NIAID has provided scientific and financial support throughout the lifecycle of this HIV vaccine concept and is contributing funding for this study along with the Bill & Melinda Gates Foundation and Vir Biotechnology, Inc., based in San Francisco. The vaccine uses a cytomegalovirus (CMV) vector, meaning a weakened version of CMV delivers the HIV vaccine material to the immune system without causing disease in study participants. NIAID has funded the discovery and development of the CMV vaccine vector since 2004. This trial is sponsored by Vir and conducted through the NIAID-funded HIV Vaccine Trials Network as study HVTN 142. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107